Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X2JM
|
|||
| Former ID |
DCL000009
|
|||
| Drug Name |
XL418
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Exelixis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H32BrF3N8O
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1N2CCN(CC2)C3=NC=NC4=NNC(=C43)Br)C(=O)CCC(F)(F)F)NCCN5CCCC5
|
|||
| InChI |
1S/C26H32BrF3N8O/c1-17-19(31-6-9-36-7-2-3-8-36)14-18(21(39)4-5-26(28,29)30)15-20(17)37-10-12-38(13-11-37)25-22-23(27)34-35-24(22)32-16-33-25/h14-16,31H,2-13H2,1H3,(H,32,33,34,35)
|
|||
| InChIKey |
IKBSEBRGSVFUHM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 871343-09-8
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00460278) Study of XL418 in Adults With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.